Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu
In Their Words

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Publications

Choueiri, TK, Hessel, C, Halabi, S, Sanford, B, Michaelson, MD, Hahn, O, Walsh, M, Olencki, T, Picus, J, Small, EJ, Dakhil, S, Feldman, DR, Mangeshkar, M, Scheffold, C, George, D, and Morris, MJ. "Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]." European Journal of Cancer (Oxford, England : 1990) 103 (November 2018): 287-null.

PMID
30270112
Full Text

Gao, X, Jegede, O, Gray, C, Catalano, PJ, Novak, J, Kwiatkowski, DJ, McKay, RR, George, DJ, Choueiri, TK, McDermott, DF, Signoretti, S, and Bhatt, RS. "Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma." Clinical Genitourinary Cancer 16, no. 5 (October 2018): 341-348.

PMID
29754934
Full Text

Zhang, T, George, DJ, and Armstrong, AJ. "Precision medicine approaches when prostate cancer Akts up." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (September 11, 2018).

PMID
30206162
Full Text

Powles, T, Motzer, RJ, Escudier, B, Pal, S, Kollmannsberger, C, Pikiel, J, Gurney, H, Rha, SY, Park, SH, Geertsen, PF, Gross-Goupil, M, Grande, E, Suarez, C, Markby, DW, Arroyo, A, Dean, M, Choueiri, TK, and George, D. "Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma." British Journal of Cancer 119, no. 6 (September 10, 2018): 663-669.

PMID
30197417
Full Text

Rini, BI, Burstein, HJ, and George, DJ. "Information Transparency in the Drug Approval Process." Jama Oncology (September 6, 2018).

PMID
30193367
Full Text

Bakthavatsalam, S, Sleeper, ML, Dharani, A, George, DJ, Zhang, T, and Franz, KJ. "Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells." Angewandte Chemie (International Ed. in English) 57, no. 39 (September 2018): 12780-12784.

PMID
30025197
Full Text

LaCroix, BL, Patierno, BM, Sullenger, BA, George, DJ, Patierno, SR, and Freedman, JA. "Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer." 10th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Atlanta, GA. September 25, 2017 - September 28, 2017.: AMER ASSOC CANCER RESEARCH, July 1, 2018.

Scholars@Duke

LaCroix, BL, Patierno, BM, Sullenger, BA, George, DJ, Patierno, SR, and Freedman, JA. "Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells." 10th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Atlanta, GA. September 25, 2017 - September 28, 2017.: AMER ASSOC CANCER RESEARCH, July 1, 2018.

Scholars@Duke

Freedman, JA, Wang, Y, Li, X, Liu, H, Moorman, PG, George, DJ, Lee, NH, Hyslop, T, Wei, Q, and Patierno, SR. "Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival." Carcinogenesis 39, no. 7 (July 2018): 879-888.

PMID
29726910
Full Text

Labriola, M, Foo, W-C, George, DJ, and Zhang, T. "Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report." Clinical Genitourinary Cancer 16, no. 3 (June 2018): e509-e512.

PMID
29636282
Full Text

Pages